Trial Profile
To assess response rates to PDL-1 inhibitor Nivolumab in lung, renal and head and neck (H&N) cancers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Lung cancer; Renal cancer
- Focus Therapeutic Use
- 13 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology